Petition Update

Clarification on previous update! Study was for ovarian and breast cancer.

Carol Carter
Lake Dallas, TX

Sep 29, 2013 — There was one clinical trial for four patient subtypes. Overall response rate 86%. This is stunning news. Great job, BioMarin - now give the drug to Andi! :-)